NCT02450838View on ClinicalTrials.gov

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Dengue
Interventions
BIOLOGICAL

V180

Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.

BIOLOGICAL

Alhydrogel™

Aluminum hydroxide gel adjuvant

BIOLOGICAL

Placebo

Trial Locations (3)

21205

Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore

05401

University of Vermont Medical Center, Burlington

05405

University of Vermont Vaccine Testing Center, Burlington

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02450838 - Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005) | Biotech Hunter | Biotech Hunter